These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20558925)

  • 1. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials.
    Wenzhen Y; Yumin L; Quanlin G; Kehu Y; Lei J; Donghai W; Lijuan Y
    Intern Med; 2010; 49(12):1103-9. PubMed ID: 20558925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials.
    Wenzhen Y; Kehu Y; Bin M; Yumin L; Quanlin G; Donghai W; Lijuan Y
    Intern Med; 2009; 48(24):2069-76. PubMed ID: 20009394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
    Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
    Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection.
    López-Góngora S; Puig I; Calvet X; Villoria A; Baylina M; Muñoz N; Sanchez-Delgado J; Suarez D; García-Hernando V; Gisbert JP
    J Antimicrob Chemother; 2015 Sep; 70(9):2447-55. PubMed ID: 26078393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
    Romano M; Marmo R; Cuomo A; De Simone T; Mucherino C; Iovene MR; Montella F; Tufano MA; Del Vecchio Blanco C; Nardone G
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):273-8. PubMed ID: 15017668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility testing before first-line treatment for
    Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
    World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance.
    Park CS; Lee SM; Park CH; Koh HR; Jun CH; Park SY; Lee WS; Joo YE; Kim HS; Choi SK; Rew JS
    Am J Gastroenterol; 2014 Oct; 109(10):1595-602. PubMed ID: 25091062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis.
    Kale-Pradhan PB; Mihaescu A; Wilhelm SM
    Pharmacotherapy; 2015 Aug; 35(8):719-30. PubMed ID: 26173786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis.
    Gingold-Belfer R; Niv Y; Schmilovitz-Weiss H; Levi Z; Boltin D
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2649-2658. PubMed ID: 34114673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
    Antos D; Schneider-Brachert W; Bästlein E; Hänel C; Haferland C; Buchner M; Meier E; Trump F; Stolte M; Lehn N; Bayerdörffer E
    Helicobacter; 2006 Feb; 11(1):39-45. PubMed ID: 16423088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis.
    Zou Y; Qian X; Liu X; Song Y; Song C; Wu S; An Y; Yuan R; Wang Y; Xie Y
    Helicobacter; 2020 Aug; 25(4):e12714. PubMed ID: 32533599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis.
    Rokkas T; Gisbert JP; Malfertheiner P; Niv Y; Gasbarrini A; Leja M; Megraud F; O'Morain C; Graham DY
    Gastroenterology; 2021 Aug; 161(2):495-507.e4. PubMed ID: 33839101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions.
    Martos M; Bujanda L; Salicio Y; Sarasqueta C; Ibarra B; Mendarte U; Fernández-Reyes M; Cosme A
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1380-4. PubMed ID: 25229983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori.
    Cosme A; Montes M; Martos M; Gil I; Mendarte U; Salicio Y; Piñeiro L; Recasens MT; Ibarra B; Sarasqueta C; Bujanda L
    Clin Microbiol Infect; 2013 Apr; 19(4):379-83. PubMed ID: 22512623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials.
    Zhang G; Zou J; Liu F; Bao Z; Dong F; Huang Y; Yin S
    Braz J Med Biol Res; 2013 Jul; 46(7):607-13. PubMed ID: 23903685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line
    Yeo YH; Shiu SI; Ho HJ; Zou B; Lin JT; Wu MS; Liou JM; Wu CY;
    Gut; 2018 Jan; 67(1):20-27. PubMed ID: 27670375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.